Antibiotic-loaded Cirsium setidens leaf extract capped Zirconium oxide nanoparticles and manufacturing method thereof
Antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract address the need for enhanced biocompatibility and antimicrobial activity, achieving improved wound healing and bacterial inhibition.
Patent Information
- Application Number
- KR1020230092663
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-07-17
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-07-17
AI Technical Summary
There is a lack of technologies that effectively combine specific antibiotics with nanoparticles derived from natural products to enhance biocompatibility, wound healing activity, and antimicrobial activity, while existing methods for nanoparticle synthesis are costly, inefficient, and potentially dangerous.
The development of antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract, where zirconia nanoparticles are synthesized using a green method involving Korean thistle leaf extract and loaded with antibiotics like ampicillin or erythromycin, enhancing biocompatibility and antibacterial activity.
The resulting nanoparticles demonstrate improved biocompatibility, wound healing activity, and antibacterial activity, as evidenced by increased wound healing and reduced bacterial growth.
Smart Images

Figure 112023078593078-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract and a method for manufacturing the same. More specifically, the invention relates to antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract, in which an antibiotic is loaded onto zirconia nanoparticles formed from Korean thistle leaf extract to enhance biocompatibility, wound healing activity, and antibacterial activity, and a method for manufacturing the same. Background Technology
[0002] Bacterial infections of wounds threaten public health and human life by delaying wound healing and causing related bacterial infections. Antibiotic treatment is considered the most effective solution for bacterial infections. However, the inappropriate or excessive use of antibiotics can lead to bacterial resistance. Treating wounds infected with pathogens is challenging due to antibiotic resistance, which delays the healing process and increases inflammatory responses. Therefore, there is an urgent need to develop new antimicrobial and wound-healing materials that effectively combat bacterial infections, promote skin incision closure, and improve the healing process. Several metallic and non-metallic nanomaterials are known to possess improved antimicrobial properties. However, most nanomaterials do not guarantee biocompatibility while exhibiting excellent antimicrobial effects.
[0003] The physical and chemical synthesis of nanoparticles frequently involves high pressure, high temperature, or toxic and destructive chemical reagents. These synthesis methods are costly, inefficient, and potentially dangerous. Meanwhile, auxiliary materials used in green or bio-based synthesis technologies are often derived from plants, microorganisms, and algae. Proteins, enzymes, sugars, and other bioactive components can be used as reducing agents in nanoparticle synthesis.
[0004] Plant extracts are the best source of natural reducing agents because they are abundant in nature, and their products or byproducts do not harm the environment. Plant parts such as roots, stems, leaves, flowers, bark, and fruits can be used for the green synthesis of nanoparticles. Furthermore, green synthesized metal and metal oxide nanoparticles exhibit higher antioxidant, antibacterial, and anticancer activities than nanoparticles synthesized through chemical or physical processes.
[0005] Zinc is an element with 40 atoms that has a unique luster similar to steel due to the frequent formation of an oxide film on its surface. ZrO2 nanoparticles are known to be an important ceramic material frequently used in bone and dental restorations due to their high temperature resistance and low toxicity.
[0006] Meanwhile, there is a lack of research on technologies that successfully combine specific antibiotics with nanoparticles derived from natural products to enhance biocompatibility, wound healing activity, and antimicrobial activity. Prior art literature
[0007] Korean Patent Publication No. 10-2022-0021882 (Published Feb. 22, 2022), "Antibiotic composition containing nanostructures" The problem to be solved
[0008] To solve the above-mentioned problems, the present invention aims to provide antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract and a method for manufacturing the same, wherein the antibiotic is loaded onto zirconia nanoparticles formed from Korean thistle leaf extract to enhance biocompatibility, wound healing activity, and antibacterial activity. means of solving the problem
[0009] To achieve the above objectives, the present invention comprises: a step (S10) for preparing a Korean thistle leaf extract, wherein the Korean thistle leaf powder, obtained by drying and grinding the Korean thistle leaves into powder, is dissolved in purified water and stirred; a step (S20) for preparing a mixed solution, wherein the Korean thistle leaf extract from the step (S10) is added dropwise to a tetrachloride zirconia solution and stirred to prepare a mixed solution; and a step (S30) for preparing zirconia nanoparticles, wherein the mixed solution prepared in the step (S20) is centrifuged to produce zirconia nanoparticles. The present invention provides a method for manufacturing antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles, characterized by including a step (S40) of manufacturing antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles, wherein one or more antibiotics, either ampicillin or erythromycin, are mixed with the zirconia nanoparticles manufactured in the above zirconia nanoparticle manufacturing step (S30), centrifuged, and freeze-dried to produce antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles.
[0010] At this time, the Korean thistle leaf extract in the above-mentioned step (S10) for preparing the Korean thistle leaf extract is characterized by dissolving the Korean thistle leaf powder, which is obtained by drying and grinding the Korean thistle leaves into powder, in purified water at a weight ratio of 1:5 and stirring at 80 to 100°C for 20 to 40 minutes.
[0011] At this time, the mixed solution in the mixed solution preparation step (S20) is characterized by adding the Korean thistle leaf extract from the Korean thistle leaf extract preparation step (S10) dropwise to the zirconia tetrachloride solution and stirring at 100 to 140 rpm at 40 to 80°C for 3 to 4 hours.
[0012] At this time, the zirconia nanoparticles in the zirconia nanoparticle manufacturing step (S30) are characterized by being manufactured by centrifuging the mixed solution prepared in the mixed solution manufacturing step (S20) at 3000 to 5000 rpm for 5 to 15 minutes.
[0013] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with antibiotics in the zirconia nanoparticle manufacturing step (S40) are characterized by being prepared by mixing one or more antibiotics, such as ampicillin or erythromycin, with the zirconia nanoparticles prepared in the zirconia nanoparticle manufacturing step (S30) at a speed of 100 to 140 rpm for 3 to 4 hours, centrifuging, and freeze-drying.
[0014] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with antibiotics in the zirconia nanoparticle manufacturing step (S40) are characterized by being prepared by mixing one or more antibiotics, either ampicillin or erythromycin, with the zirconia nanoparticles manufactured in the zirconia nanoparticle manufacturing step (S30), centrifuging at 3000 to 5000 rpm for 5 to 15 minutes, and freeze-drying for 8 to 16 hours.
[0015] In addition, the present invention provides antibiotic-loaded zirconia nanoparticles containing a Korean thistle leaf extract capped with a mixture of zirconia nanoparticles prepared by centrifuging a mixture of zirconia nanoparticles prepared by adding dropwise a Korean thistle leaf extract (formed by dissolving and stirring a Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into a zirconia tetrachloride solution) and stirring, and zirconia nanoparticles prepared by centrifuging one or more antibiotics selected from ampicillin or erythromycin, centrifuging, and freeze-drying.
[0016] At this time, the above-mentioned Korean thistle leaf extract is characterized by being prepared by dissolving Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, in purified water at a weight ratio of 1:5 and stirring at 80 to 100°C for 20 to 40 minutes.
[0017] At this time, the above mixed solution is characterized by being prepared by adding the above Korean thistle leaf extract dropwise to the above zirconia tetrachloride solution and stirring at 100 to 140 rpm at 40 to 80°C for 3 to 4 hours.
[0018] At this time, the zirconia nanoparticles are characterized by being prepared by centrifuging the mixed solution at 3000 to 5000 rpm for 5 to 15 minutes.
[0019] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with the antibiotic are characterized by being prepared by mixing one or more antibiotics, either ampicillin or erythromycin, with the zirconia nanoparticles at a speed of 100 to 140 rpm for 3 to 4 hours, centrifuging, and freeze-drying.
[0020] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with the antibiotic are characterized by being prepared by mixing one or more antibiotics, either ampicillin or erythromycin, with the zirconia nanoparticles, centrifuging at 3000 to 5000 rpm for 5 to 15 minutes, and freeze-drying for 8 to 16 hours. Effects of the invention
[0021] The antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract according to the manufacturing method of the present invention are formed by loading an antibiotic onto zirconia nanoparticles formed from Korean thistle leaf extract, thereby increasing biocompatibility, wound healing activity, and antibacterial activity. Brief explanation of the drawing
[0022] Figure 1 shows images of UV-Vis absorption spectroscopy of green synthetic ZrO2NPs using CSE (A), XRD pattern images of ZrO2NPs (B), transmission electron microscopy observation images of ZrO2NPs at two different magnifications such as 200 nm and 100 nm (C and D), and images of energy dispersive X-ray spectroscopy analysis (E). Figure 2 is an FTIR analysis image of CSE, ampicillin, erythromycin, ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs. Figure 3 is an image regarding the hemolytic activity experiment of ZrO2NPs, ZrO2-Amp NPs, ZrO2-Ery NPs, ampicillin, and erythromycin. Figure 4 shows images (A) of cytotoxicity tests of antibiotics (ampicillin and erythromycin) and pure or antibiotic-loaded ZrO2NPs (ZrO2NPs, ZrO2-Amp NPs, ZrO2-Ery NPs) in NIH3T3 cell lines, and images (B) of cell death stage analysis (AO / EB) staining analysis by acridine orange / ethidium bromide. Figure 5 shows images regarding the analysis of chick chorionic villi (CAM) for ZrO2 NPs, ZrO2-Amp NPs, ZrO2-Ery NPs, ampicillin, and erythromycin. (Egg embryos treated with 200 μL of NaOH (1 M) show hemorrhage, coagulation, and PBS.) Figure 6 is an image regarding the in vitro wound healing activity experiment of ZrO2NPs, ZrO2-Amp NPs, ZrO2-Ery NPs, ampicillin, and erythromycin in NIH3T3 cell lines. (Magnification: 4x, scale bar 200 μm). Figure 7 is an image regarding an experiment measuring the wound healing area using the imageJ software tool. Figure 8 is an image regarding an experiment observing the viability of bacteria (E. coli) induced by treatment with nanoparticles (ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs) using SYTO9 and PI staining methods. Figure 9 shows images regarding the viability observation experiment of bacteria (B. cereus) induced by nanoparticle (ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs) treatment using SYTO9 and PI staining methods. Specific details for implementing the invention
[0023] The following detailed descriptions relating to the present invention refer to the accompanying drawings, which are embodiments in which the present invention may be practiced and are illustrated as examples of such embodiments. These embodiments are described in detail to sufficiently enable those skilled in the art to practice the present invention. It should be understood that various embodiments of the present invention are different but need not be mutually exclusive. For example, specific shapes, structures, and characteristics described herein may be implemented in different embodiments without departing from the spirit and scope of the present invention in relation to one embodiment. Furthermore, it should be understood that the location or arrangement of individual components within each described embodiment may be changed without departing from the spirit and scope of the present invention.
[0024] Accordingly, the following detailed description is not intended to be taken in a limiting sense, and the scope of the invention is limited only by the appended claims, including all equivalents to those claimed therein, provided they are properly described. Similar reference numerals in the drawings refer to the same or similar functions across various aspects.
[0025] The terms used in this invention have been selected based on currently widely used general terms, taking into account their functions within the invention; however, these terms may vary depending on the intent of those skilled in the art, case law, the emergence of new technologies, etc. Additionally, in specific cases, terms have been arbitrarily selected by the applicant, and in such cases, their meanings will be described in detail in the relevant description of the invention. Therefore, the terms used in this invention should be defined not merely by their names, but based on their meanings and the overall content of the invention.
[0026] In the present invention, when a part is described as “comprising” a certain component, this means that, unless specifically stated otherwise, it does not exclude different components but may include additional different components.
[0028] Hereinafter, the antibiotic-loaded zirconia leaf extract capping zirconia nanoparticles and the method of preparation according to the present invention will be described in detail.
[0030] To achieve the above objectives, the present invention comprises: a step (S10) for preparing a Korean thistle leaf extract, wherein the Korean thistle leaf powder, obtained by drying and grinding the Korean thistle leaves into powder, is dissolved in purified water and stirred; a step (S20) for preparing a mixed solution, wherein the Korean thistle leaf extract from the step (S10) is added dropwise to a tetrachloride zirconia solution and stirred to prepare a mixed solution; and a step (S30) for preparing zirconia nanoparticles, wherein the mixed solution prepared in the step (S20) is centrifuged to produce zirconia nanoparticles. The present invention provides a method for manufacturing antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles, characterized by including a step (S40) of manufacturing antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles, wherein one or more antibiotics, either ampicillin or erythromycin, are mixed with the zirconia nanoparticles manufactured in the above zirconia nanoparticle manufacturing step (S30), centrifuged, and freeze-dried to produce antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles.
[0032] First, the step of manufacturing Korean thistle leaf extract (S10) is performed.
[0033] In the above step of preparing the Korean thistle leaf extract (S10), the Korean thistle leaf powder, which is obtained by drying and grinding the Korean thistle leaves into powder, is dissolved in purified water and stirred to prepare the Korean thistle leaf extract.
[0034] At this time, the Korean thistle leaf extract in the above step (S10) of preparing the Korean thistle leaf extract is suitablely prepared by dissolving the Korean thistle leaf powder, which is obtained by drying and grinding the Korean thistle leaves into powder, in purified water at a weight ratio of 1:5 and stirring at 80 to 100°C for 20 to 40 minutes.
[0035] As a more specific example, the Korean thistle leaf extract in the above-mentioned step (S10) for preparing the Korean thistle leaf extract is suitablely prepared by dissolving the Korean thistle leaf powder, which is obtained by drying and grinding the Korean thistle leaves into powder, in purified water at a weight ratio of 1:5 and stirring at 90°C for 30 minutes.
[0037] Next, the mixed solution preparation step (S20) is performed.
[0038] In the above mixed solution preparation step (S20), the Korean thistle leaf extract from the above Korean thistle leaf extract preparation step (S10) is added dropwise to the zirconia tetrachloride solution and stirred to prepare a mixed solution.
[0039] At this time, the mixed solution in the mixed solution preparation step (S20) is appropriately prepared by adding the Korean thistle leaf extract from the Korean thistle leaf extract preparation step (S10) dropwise to the zirconia tetrachloride solution and stirring at 100 to 140 rpm at 40 to 80°C for 3 to 4 hours.
[0040] As a more specific example, the mixed solution in the above mixed solution preparation step (S20) is appropriately prepared by adding the Korean thistle leaf extract from the above Korean thistle leaf extract preparation step (S10) dropwise to the above zirconia tetrachloride solution and stirring at 120 rpm at 60°C for 4 hours.
[0042] Next, the zirconia nanoparticle manufacturing step (S30) is performed.
[0043] In the above zirconia nanoparticle manufacturing step (S30), the mixed solution prepared in the above mixed solution manufacturing step (S20) is centrifuged to produce zirconia nanoparticles.
[0044] At this time, the zirconia nanoparticles in the zirconia nanoparticle manufacturing step (S30) are suitable for being manufactured by centrifuging the mixed solution prepared in the mixed solution manufacturing step (S20) at 3000 to 5000 rpm for 5 to 15 minutes.
[0045] As a more specific example, the zirconia nanoparticles in the zirconia nanoparticle manufacturing step (S30) are suitable for being manufactured by centrifuging the mixed solution prepared in the mixed solution manufacturing step (S20) at 4000 rpm for 10 minutes.
[0047] Next, the step of manufacturing zirconia nanoparticles capped with antibiotic-loaded Cirsium japonicum leaf extract (S40) is performed.
[0048] In the step (S40) of manufacturing zirconia nanoparticles capped with Korean thistle leaf extract loaded with the above antibiotic, one or more antibiotics, either ampicillin or erythromycin, are mixed with the zirconia nanoparticles manufactured in the step (S30) of manufacturing zirconia nanoparticles, centrifuged, and freeze-dried to manufacture zirconia nanoparticles capped with Korean thistle leaf extract loaded with the above antibiotic.
[0049] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with antibiotics in the zirconia nanoparticle manufacturing step (S40) are appropriately prepared by mixing one or more antibiotics, such as ampicillin or erythromycin, with the zirconia nanoparticles prepared in the zirconia nanoparticle manufacturing step (S30) at a speed of 100 to 140 rpm for 3 to 4 hours, centrifuging, and freeze-drying.
[0050] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with antibiotics in the zirconia nanoparticle manufacturing step (S40) are preferably prepared by mixing one or more antibiotics, such as ampicillin or erythromycin, with the zirconia nanoparticles prepared in the zirconia nanoparticle manufacturing step (S30), centrifuging at 3000 to 5000 rpm for 5 to 15 minutes, and freeze-drying for 8 to 16 hours.
[0051] As a more specific example, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with antibiotics in the zirconia nanoparticle manufacturing step (S40) are appropriately prepared by mixing one or more antibiotics, either ampicillin or erythromycin, with the zirconia nanoparticles prepared in the zirconia nanoparticle manufacturing step (S30) at a speed of 120 rpm for 4 hours, centrifuging at 4000 rpm for 10 minutes, and freeze-drying for 12 hours.
[0053] In addition, the present invention provides antibiotic-loaded zirconia nanoparticles containing a Korean thistle leaf extract capped with a mixture of zirconia nanoparticles prepared by centrifuging a mixture of zirconia nanoparticles prepared by adding dropwise a Korean thistle leaf extract (formed by dissolving and stirring a Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into a zirconia tetrachloride solution) and stirring, and zirconia nanoparticles prepared by centrifuging one or more antibiotics selected from ampicillin or erythromycin, centrifuging, and freeze-drying.
[0055] At this time, the above Korean thistle leaf extract is suitablely prepared by dissolving Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, in purified water at a weight ratio of 1:5 and stirring at 80 to 100°C for 20 to 40 minutes.
[0056] As a more specific example, the above Korean thistle leaf extract is suitablely prepared by drying and grinding Korean thistle leaves to make powder, dissolving the Korean thistle leaf powder in purified water at a weight ratio of 1:5, and stirring at 90°C for 30 minutes.
[0058] At this time, the above mixed solution is suitablely prepared by adding the above Korean thistle leaf extract dropwise to the above zirconia tetrachloride solution and stirring at 100 to 140 rpm at 40 to 80°C for 3 to 4 hours.
[0059] As a more specific example, the above mixed solution is suitablely prepared by adding the above Korean thistle leaf extract dropwise to the above zirconia tetrachloride solution and stirring at 120 rpm at 60°C for 4 hours.
[0061] At this time, the zirconia nanoparticles are preferably prepared by centrifuging the mixed solution at 3000 to 5000 rpm for 5 to 15 minutes.
[0062] As a more specific example, the zirconia nanoparticles are suitablely prepared by centrifuging the mixed solution at 4000 rpm for 10 minutes.
[0064] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with the antibiotic are preferably prepared by mixing one or more antibiotics, such as ampicillin or erythromycin, with the zirconia nanoparticles at a speed of 100 to 140 rpm for 3 to 4 hours, centrifuging, and freeze-drying.
[0065] At this time, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with the antibiotic are preferably prepared by mixing one or more antibiotics, such as ampicillin or erythromycin, with the zirconia nanoparticles, centrifuging at 3000 to 5000 rpm for 5 to 15 minutes, and freeze-drying for 8 to 16 hours.
[0066] As a more specific example, the zirconia nanoparticles capped with Korean thistle leaf extract loaded with the above antibiotic are appropriately prepared by mixing one or more antibiotics, either ampicillin or erythromycin, with the zirconia nanoparticles at a speed of 120 rpm for 4 hours, centrifuging at 4000 rpm for 10 minutes, and freeze-drying for 12 hours.
[0068] Below, the effects of zirconia nanoparticles capped with Korean thistle leaf extract loaded with antibiotics according to the manufacturing method of the present invention will be examined in detail through the following comparative examples and experimental examples.
[0070] 1. Materials and Methods
[0071] 1.1. Materials Cirsium setidens ( CS )
[0072] Leaves were collected from the mountain of Kangwon National University in Chuncheon, Gangwon-do, South Korea. Zirconia (IV) chloride (high-purity analytical reagent, 99.99%), acridine orange (AO), ethidium bromide (EB), sodium hydroxide (NaOH), ampicillin sodium salt, erythromycin, and Triton X-100 were purchased from Sigma Aldrich (St. Louis, MO, USA). Poison blood (laboratory use only) was purchased from Biozoa Biological Supply Co, Ltd in Seoul, South Korea. Hatching chick eggs were purchased from a local store in Chuncheon, Gangwon-do, South Korea. Mouse fibroblast (NIH3T3) cell lines were purchased from the Korean Cell Line Bank (KCLB) in Seoul, South Korea. Dulbecco's modified eagle media (DMEM), fetal bovine serum (FBS), penicillin and streptomycin (P&S), trypsin-EDTA, and SYTO-9 / propidium iodide (PI) were purchased from ThermoFishers Scientific, Waltham, MA, USA. The water-soluble tetrazolium (WST)-1 assay kit was purchased from EZ-CyTox at the Daiel Research Institute in Seoul, South Korea. 94.5% ethyl alcohol was purchased from Daejung, Chemicals and Metals Co, Ltd, located in Gyeonggi-do, South Korea. Pathogens such as Bacillus cereus ATCC 14579, Staphylococcus aureus ATCC 19095, Escherichia coli ATCC 43888, and Salmonella enterica ATCC 14028 were obtained from the Korean Center for Microbiology, South Korea.
[0074] 1.1. Ampicillin-loaded Silybum marianum leaf extract capping zirconia nanoparticles (ZrO₂ 2 -Amp NPs Manufacturing of )
[0075] Zirconia nanoparticles (ZrO2-Amp NPs) capped with ampicillin-loaded Korean thistle leaf extract were prepared according to the following manufacturing method.
[0076] Step for preparing Korean thistle leaf extract (S10): Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, was dissolved in purified water at a weight ratio of 1:5 and stirred at 90°C for 30 minutes to prepare Korean thistle leaf extract.
[0077] Mixed solution preparation step (S20): The Korean thistle leaf extract from the Korean thistle leaf extract preparation step (S10) was added dropwise to the zirconia tetrachloride solution and stirred at 120 rpm at 60°C for 4 hours to prepare a mixed solution.
[0078] Zirconia nanoparticle manufacturing step (S30): Zirconia nanoparticles were manufactured by centrifuging the mixed solution prepared in the mixed solution manufacturing step (S20) at 4000 rpm for 10 minutes.
[0079] Step of preparing antibiotic-loaded zirconia nanoparticles (S40): The zirconia nanoparticles prepared in the step of preparing zirconia nanoparticles (S30) were mixed with ampicillin at a speed of 120 rpm for 4 hours, centrifuged at 4000 rpm for 10 minutes, and freeze-dried for 12 hours to prepare ampicillin-loaded Silybum marianum leaf extract-capped zirconia nanoparticles (ZrO2-Amp NPs).
[0081] 1.2. with erythromycin Loaded Korean thistle leaf extract capping zirconia nanoparticles (ZrO₂) 2 -Ery NPs Manufacturing of )
[0082] Zirconia nanoparticles (ZrO2-Ery NPs) capped with erythromycin-loaded Korean thistle leaf extract were prepared according to the following manufacturing method.
[0083] Step for preparing Korean thistle leaf extract (S10): Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, was dissolved in purified water at a weight ratio of 1:5 and stirred at 90°C for 30 minutes to prepare Korean thistle leaf extract.
[0084] Mixed solution preparation step (S20): The Korean thistle leaf extract from the Korean thistle leaf extract preparation step (S10) was added dropwise to the zirconia tetrachloride solution and stirred at 120 rpm at 60°C for 4 hours to prepare a mixed solution.
[0085] Zirconia nanoparticle manufacturing step (S30): Zirconia nanoparticles were manufactured by centrifuging the mixed solution prepared in the mixed solution manufacturing step (S20) at 4000 rpm for 10 minutes.
[0086] Step of preparing antibiotic-loaded zirconia nanoparticles (S40): Erythromycin was mixed with the zirconia nanoparticles prepared in the step of preparing zirconia nanoparticles (S30) at a speed of 120 rpm for 4 hours, centrifuged at 4000 rpm for 10 minutes, and freeze-dried for 12 hours to prepare erythromycin-loaded Korean thistle leaf extract-capped zirconia nanoparticles (ZrO2-Ery NPs).
[0088] 1.3. Comparative example 1. Korean thistle leaf extract ( CSE Manufacturing of )
[0089] Korean thistle leaf extract (CSE) was prepared according to the following process.
[0090] Step for preparing Korean thistle leaf extract (S10): Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, was dissolved in purified water at a weight ratio of 1:5 and stirred at 90°C for 30 minutes to prepare Korean thistle leaf extract (CSE).
[0092] 1.4. Comparative example 2. Zirconia nanoparticles ( ZrO2 NPs Manufacturing of )
[0093] Zirconia nanoparticles (ZrO2NPs) were prepared according to the following process.
[0094] Step for preparing Korean thistle leaf extract (S10): Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, was dissolved in purified water at a weight ratio of 1:5 and stirred at 90°C for 30 minutes to prepare Korean thistle leaf extract.
[0095] Mixed solution preparation step (S20): The Korean thistle leaf extract from the Korean thistle leaf extract preparation step (S10) was added dropwise to the zirconia tetrachloride solution and stirred at 120 rpm at 60°C for 4 hours to prepare a mixed solution.
[0096] Zirconia nanoparticle manufacturing step (S30): Zirconia nanoparticles (ZrO2NPs) were manufactured by centrifuging the mixed solution prepared in the mixed solution manufacturing step (S20) at 4000 rpm for 10 minutes.
[0098] 1.5. Comparative example 3. Ampicillin ( Ampicillin Preparation of )
[0099] Ampicillin was purchased from Sigma Aldrich (St. Louis, MO, USA) and prepared.
[0101] 1.6. Comparative example 4. Erythromycin's preparation
[0102] Erythromycin was purchased from Sigma Aldrich (St. Louis, MO, USA) and prepared.
[0104] 2. Experimental Method
[0105] 2.1. In vivo chicks chorioallantoic Mak ( CAM ) analyze
[0106] The effects of ZrO2 nanoparticles, ZrO2-Amp nanoparticles, and ZrO2-Ery nanoparticles on chick embryos were evaluated. The surface of the fertilized eggs was cleaned using 70% ethanol. Then, the eggshells were gently opened and the inner membranes were removed. Subsequently, 200 μL of ZrO2 NPs (1 mg / mL), ZrO2-Amp NPs (1 mg / mL), ZrO2-Ery NPs (1 mg / mL), PBS, and 1 M NaOH were added to the egg embryos and incubated. After 5 minutes, samples were examined to determine whether they caused changes in the blood vessels of the egg embryos.
[0108] 2.2. Hemolysis Analysis
[0109] Hemolysis analysis was performed according to known methods. 1 mL of sheep erythrocytes was mixed with 9 mL of PBS, centrifuged at 2000 rpm for 10 minutes, and washed three times with PBS. Subsequently, sheep erythrocytes were dispersed in PBS at a concentration of 4% (v / v). Different concentrations of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs (31.25, 62.5, 125, 250, 500, 1000 μg / mL) were mixed in a 1:1 ratio, centrifuged at 2000 rpm, incubated at 37°C for 1 hour, and then 10 minutes. The absorbance of the supernatant was measured at 545 nm using a microplate reader. Triton X-100 (1% v / v) was used as a negative control, and PBS was used as a positive control.
[0111] 2.3. In Vitro Cytotoxicity Test
[0112] The cytotoxicity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs was investigated in mouse fibroblast cells (NIH3T3 cell line) according to known methods. In summary, NIH3T3 cells were cultured in DMEM (10% FBS, 1% PS) at 37°C in a 5% CO2 incubator. Then, cells (1.0 × 10⁴ cells / mL) were grown in 96-well plates for 24 hours. Subsequently, 10 μL of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs (1000, 500, 250, 125, 62.5, and 31.25 μg / mL) were added for 24 hours. Afterward, 10 μL of WST-1 reagent was added to each well and incubated for 3 hours under the above conditions. Then, absorbance was evaluated using a microplate reader at 450 nm. Subsequently, in vitro cytotoxicity was also investigated using the AO / EB staining method.
[0114] 2.4. Analysis of In Vitro Wound Healing
[0115] The wound healing activity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs was evaluated by an in vitro wound healing assay. NIH3T3 cells were cultured in DMEM (10% FBS, 1% P&S) in an incubator (5% CO2, 37°C) until the cells reached 80–90% confluence. Then, cells were collected after treatment with 1X Trypsin-EDTA and 1 mL (1 x 10⁶) 4Cells (cells / mL) were seeded into 12-well plates and grown for 24 hours under the above conditions. DMEM was removed, and a straight scratch line was made in the center of each well using a 200 μL microtip, followed by washing with PBS. Then, a sample containing DMEM (100 μg / mL) was added to each well. Finally, wound healing was observed at different time intervals (0, 12, 24, and 48 hours) using an optical microscope. The wound site was measured using ImageJ software. The percentage of wound healing was calculated using the formula described below.
[0116] Wound healing area (%) = (Wound healing area (initial h) - Wound healing area (final h)) / (Wound healing area (initial h)) × 100
[0118] 2.5. Antimicrobial Analysis
[0119] 2.5.1. Well Diffusion Analysis
[0120] The bacterial inhibitory activity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs was measured according to previously reported methods. Pathogens including S. aureus, B. cereus, E. coli, and S. enterica were cultured in 10 mL of MHB medium and stored overnight in a shaking incubator at 37 °C. Bacterial suspensions were spread onto MHA medium, and sterile stainless steel Corer wells (5 mm) were prepared. Each well was filled with 30 μL of bare and antibiotic-loaded ZrO2NPs at different concentrations (125, 250, 500, and 1000 μg / mL). All plates were incubated at 37 °C for 24 hours. 30 μL of ampicillin (1 mg / mL) and erythromycin (1 mg / mL) were used as positive controls, and the results were indicated as inhibition zones (mm).
[0121] 2.5.2. MIC and MBC measurements
[0122] Bacterial pathogens were cultured in MHB and stored in a shaking incubator for 24 hours. 100 μL of MHB containing different concentrations of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs (39–1000 μg / mL) was seeded into a 96-well plate, and then 10 μL of bacterial suspension was added. The plates were then incubated at 37°C for 24 hours. Afterward, optical density (OD) was measured at 600 nm. Untreated bacterial cultures were considered as a control. MIC and MBC were measured by comparing the OD values of treated bacterial cells with those of untreated bacterial cells. Additionally, bacterial suspensions from the treated wells were cultured on MHA plates, and bacterial colonies were observed to evaluate MBC values.
[0123] 2.5.3. SYTO 9 and PI ( LIVE / DEAD ™ BacLight ™Analysis
[0124] The effects of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs treatment on bacterial cell survival / death were measured by SYTO 9 and PI (LIVE / DEAD™BacLight™ staining assay) according to known methods. Treated or untreated bacterial cells were stained with SYTO 9 and PI according to the manufacturer's instructions and observed on a confocal microscopy imaging system (Carl Zeiss LSM880 including Airyscan).
[0126] 2.6. Statistical Analysis
[0127] All experiments were repeated three times, and experimental data were expressed as mean ± standard deviation (SD). Statistical significance was analyzed using ANOVA. A P value of less than 0.5 was considered statistically significant.
[0129] 3. Results and Discussion
[0130] 3.1. ZrO 2 NPs , ZrO 2 - Amp NPs and ZrO 2 - Ery Synthesis of NPs
[0131] A color change in the reaction solution indicates the formation of nanoparticles. This was confirmed by a UV-visible spectrophotometer. In this study, the addition of CSE to a ZrOCl2.8H2O solution resulted in a color change from clear white to cloudy milky white. This result indicates that ZrOCl2.8H2O is converted into ZrO2NPs. Additionally, the UV spectrum showed absorption peaks for CSE and ZrO2NPs at 290 nm and 340 nm, respectively, ranging from oxides to zirconia cations (Fig. 1A). These UV absorption peaks demonstrate the relevance of Korean thistle extract (CSE) as a capping agent in the synthesis of ZrO2NPs.
[0133] 3.2. Characteristic Verification
[0134] 3.2.1. XRD analyze
[0135] XRD is frequently applied to the characterization of nanoparticles to investigate the distribution and structure of internal atoms. The crystallographic properties of ZrO2NPs were investigated by XRD (Fig. 1B). Major diffraction peaks of 2θ corresponding to (110), (111), (200), (102), (220), (311), and (400) were observed at 24.54, 28.24, 33.17, 40.39, 49.96, 58.64, and 70.81. These characteristic diffraction peaks were consistent with the standard monoclinic and tetragonal structures of ZrO2 (JCPDS: 37-1484 and 42-1164). Additionally, some peaks corresponding to CSE, which were not identified in the XRD patterns of ZrO2NPs, were observed. Overall, XRD patterns showed that the ZrO2 nanoparticles have monoclinic and tetragonal structures.
[0136] 3.2.2. TEM -EDS Analysis
[0137] TEM was used to investigate the microstructure, distribution, and size of ZrO2 nanoparticles. TEM images of ZrO2 NPs at different nanoscales are shown in Fig. 1 (Fig. 1 C and D). The results show that the ZrO2 NPs are irregularly spherical and have a size of <200 nm. The size and shape of the ZrO2 NPs may vary depending on the ratio of plant extract to zirconia salt. The presence of oxygen (O), carbon (C), nitrogen (N), and zirconia (Zr) within the ZrO2 nanoparticles was confirmed by EDS analysis (Fig. 1 E). The EDS spectrum showed peaks at 0.5 keV for O and 2.2 keV for Zr, indicating the composition of the crystalline ZrO2 NPs. Furthermore, the absence of any further spurious peaks in the EDS spectrum confirmed high purity.
[0138] 3.2.3. FTIR analyze
[0139] Polyphenols, flavonoids, polysaccharides, saponins, and amino acids were among the bioactive components found in CSE. These bioactive components from different sources are often used as bioreducing agents in the synthesis of ZrO2NPs. FTIR analysis was performed to identify the functional groups of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-EryNPs. Changes in functional groups were observed before and after nanoparticle formation, and before and after antibiotic loading. The main peaks of CSE were 3194, 1561, 1349, 1065, 981, 832, 808, 665, and 541 cm⁻¹. -1 It appeared in (Fig. 2). ZrO2NPs were 3119, 1615, 1408, 1019, and 913 cm⁻¹. -1 Vibrational coupling was shown at 3194 and 3119 cm⁻¹. The stretching vibrations of the -OH group were 3194 and 3119 cm⁻¹. -1 It corresponds to the peak at. The comparison between CSE and ZrO2NPs shows the change in -OH groups before and after synthesis due to residual moisture or absorption from the atmosphere during the synthesis process. The NH and CO stretching vibrations are 1561 and 1615 cm⁻¹, respectively. -1 It was responsible for absorption. The peaks are at 1349 and 1408 cm⁻¹. -1 It appeared at, indicating the presence of OH modification in the C-OH group. Additionally, the CSE is 1065 cm⁻¹. -1 An amine (CN) was shown at 832 cm⁻¹ and an alkyl halide at 832 cm⁻¹. The presence of carboxyl and amide groups in CSE may be related to the biological reduction of zirconia ions to ZrO₂NPs. 913 to 1019 cm⁻¹ -1The absorption peaks between them represent Zr-O-Zr vibrations. There were significant changes in the FTIR spectra of bare ZrO2NPs and antibiotics loaded onto ZrO2NPs. The spectra of ZrO2-Amp NPs and ZrO2-Ery NPs are distinguished from ZrO2NPs by the presence of peaks associated with the amino and amide groups of the antibiotics. Several significant differences appear when comparing pure ZrO2NPs with antibiotic-loaded ZrO2NPs (ampicillin and erythromycin). For example, in ZrO2-Amp NPs, 1776, 1504, 1300, 1251, and 696 cm⁻¹ -1 A new peak was present and matched the functional group of ampicillin. The FTIR spectrum of ZrO2-Ery NPs showed peaks at 1389, 1206, 1118, 999, and 778 cm⁻¹ corresponding to erythromycin. -1 An additional peak was observed. These results indicate that ZrO2-Amp NPs, ZrO2-Ery NPs, and ZrO2 NPs were successfully synthesized.
[0140] 3.2.4. DLS and ELS analyze
[0141] The particle size distribution, stability, and zeta potential of nanoparticles are essential characterization factors of nanoparticles. The particle size distribution and zeta potential of ZrO2 nanoparticles are shown in Table 1.
[0142] Nanoparticles Size (d.nm) PDI Zeta potential (mV) ZrO2 NPs 54.67 ± 3.89 0.660 -7.79 ± 1.06 ZrO2?Amp NPs 73.99 ± 6.79 0.363 -38.1 ± 3.91 ZrO2?Ery NPs 80.41 ± 4.62 0.300 -13.5 ± 2.17
[0143] The average diameter of ZrO2NPs was 54.67 ± 3.89 d.nm, with a PDI of 0.660 and a zeta potential of -7.79 ± 1.06 mV. The negative zeta potential indicates the capping molecules of CSE. Additionally, the average diameters of ZrO2-Amp NPs and ZrO2-Ery NPs were 73.99 ± 6.79 d.nm and 80.41 ± 4.62 d.nm, respectively; their PDIs were 0.363 and 0.300, and their zeta potentials were -38.1 ± 3.91 mV and -13.5 ± 2.17 mV, respectively. Size differences occurred between the nanoparticles due to antibiotic loading. The sizes of ZrO2-Amp NPs and ZrO2-Ery NPs were found to be larger than those of pure ZrO2NPs. These results indicate that the antibiotics successfully bound to the nanoparticles, causing a change in their size. The zeta potential varied significantly among the nanoparticles. Additionally, a PDI < 0.5 indicated the stability of the nanoparticles.
[0145] 3.3. Hemolysis Analysis
[0146] The blood cell compatibility of ZrO2NPs, ZrO2-Amp NPs, ZrO2-Ery NPs, ampicillin, and erythromycin was tested by hemolysis assay. The release of hemoglobin from red blood cells due to exposure to ZrO2NPs, ZrO2-Amp NPs, ZrO2-Ery NPs, ampicillin, and erythromycin was measured as an indicator of red blood cell lysis. 100 μL of different concentrations of ZrO2NPs, ZrO2-Amp NPs, ZrO2-Ery NPs, ampicillin, and erythromycin (15.62–500 μg / mL) were incubated with red blood cells at 37°C for 1 hour (Fig. 3). Treatment with Triton X-100 achieved over 96% hemolysis. As a result, none of the nanoparticles were found to cause serious toxicity to red blood cells. The hemolytic rates ranged from 2.75 to 3.87% for ZrO2 NPs, 2.32 to 4.23% for ZrO2-Amp NPs, and 2.57 to 4.66% for ZrO2-Ery NPs. Additionally, the hemolytic rates for ampicillin and erythromycin were 2.84 to 5.67% and 2.5 to 5.48%, respectively. According to ASTM E2524-08 standards, red blood cells are not suitable for clinical trials if the hemolytic rate exceeds 5%. Hemolysis of more than 5% was observed for both ampicillin and erythromycin at 500 μg / mL, but hemolysis of less than 5% was observed for ZrO2-Amp NPs and ZrO2-Ery NPs at 500 μg / mL, confirming that biocompatibility was enhanced due to the binding according to the present invention.
[0148] 3.4. Cytotoxicity Analysis
[0149] ZrO2 nanoparticles are frequently used as biomaterials for dental restorations due to their stability and biocompatibility. In this invention, ZrO2 nanoparticles were synthesized using CSE, and then two types of antibiotic molecules were loaded to enhance antimicrobial activity.
[0150] The cytotoxicity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs was investigated in NIH3T3 cell lines. The toxicity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs was found to be lower than that of ampicillin and erythromycin (Fig. 4A). In addition, the toxicity of the two antibiotics, ampicillin and erythromycin, was reduced by encapsulation with ZrO2 nanoparticles.
[0151] Fluorescence staining was also used to confirm the cytotoxicity of the nanoparticles. Acridine orange (AO) passes through intact cell membranes and inserts into nuclear DNA to emit green fluorescence, whereas EB (ethidium bromide) penetrates only damaged cell membranes and inserts into nuclear DNA, emitting orange fluorescence. Cells were treated with ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs (100 μg / mL), followed by AO / EB staining. The results showed that ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs were non-cytotoxic to NIH3T3 cells, while both antibiotics exhibited moderate cytotoxicity (Fig. 4. B).
[0153] 3.5. CAM analyze
[0154] CAM analysis is suitable for studying angiogenesis, tumor formation, and in vivo toxicity. The CAM analysis model offers the advantages of lower cost and time savings compared to in vivo toxicity studies. Therefore, the toxicity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs was measured by CAM analysis. Oocyte embryos treated with ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs did not affect neurogenesis or coagulation compared to the negative control (1M NaOH). In contrast, antibiotic treatment showed slight vascular rupture (Fig. 5). These results demonstrate the non-toxicity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs.
[0156] 3.6. Analysis of In Vitro Wound Healing
[0157] A wound healing assay was performed to evaluate the wound healing effect on NIH3T3 cells (Fig. 6). ZrO2-Amp NPs and ZrO2-Ery NPs significantly enhanced the proliferation of NIH3T3 cells within 12 hours compared to the control group and the two antibiotics. As a result of checking the wound healing area for each treatment at 12 hours with the control group (43.14 ± 1.26%), ZrO2NPs (56.47 ± 2.78%), ZrO2-Amp NPs (55.34 ± 2.01%), ZrO2-Ery NPs (43.86 ± 1.08%), ampicillin (43.65 ± 1.4%), and erythromycin (40.77 ± 21.72%), at 24 hours, cells treated with ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs grew in the maximum area, whereas scattered cell growth was observed in the control group (Fig. 7). ZrO2NPs showed a superior cell growth-promoting effect compared to the control group, which appears to be due to the self-effect and the capping of the Korean thistle leaf extract (CSE) molecules. Korean thistle leaf extract (CSE) contains specific minerals and nutrients, and the process of obtaining ZrO2-Amp NPs and ZrO2-Ery NPs through green synthesis implies that the maximum amount of Korean thistle leaf extract (CSE) components is maintained. The healing efficiency of ZrO2-Amp NPs and ZrO2-Ery NPs was lower than that of ZrO2 NPs but higher than that of the untreated control group and the antibiotic group (ampicillin and erythromycin). These results indicate that ZrO2-Amp NPs and ZrO2-Ery NPs still possess the efficiency to stimulate cell growth even after antibiotic loading.
[0159] 3.7. Antimicrobial Analysis
[0160] Well-diffusion and microdilution methods were used to investigate the antimicrobial activity of ZrO2NPs, ZrO2-Amp NPs, and ZrO2-Ery NPs. In the well-diffusion assay, CSE and ZrO2 nanoparticles did not exhibit inhibition zones against the four pathogens. However, ZrO2 nanoparticles containing antibiotics showed higher inhibition zones against E. coli and B. cereus. ZrO2-Amp NPs (30 μg) showed inhibition zones of 18 mm and 17 mm against E. coli and B. cereus, respectively. On the other hand, ZrO2-Ery NPs (30 μg) showed inhibition zones of 17 mm and 14.5 mm against E. coli and B. cereus, respectively (Table 2).
[0161] Pathogens Samples Zone of inhibition (mm) 3.75 (μg) 7.5 (μg) 15 (μg) 30 (μg) Ampicillin 30 (μg) Erythromycin 30 (μg) E coil ZrO2-Amp NPs 11.5 13.5 17.5 18 17 - ZrO2-Ery NPs 7.3 12.5 14 17 - 17.5 S entrica ZrO2-Amp NPs 6.5 11.5 14 16 13.5 - ZrO2-Ery NPs 3 5 5 5 - 17 S aureus ZrO2-Amp NPs 5 5 5 5 13 - ZrO2-Ery NPs 5 5 5 5 - 16.5 B cereus ZrO2-Amp NPs 13 14.5 16 17 16.5 - ZrO2-Ery NPs 10 11.5 12 14.5 - 15.5
[0162] The antibacterial effect of ampicillin (30 μg) was similar to that of ~15 μg of ZrO2-Amp NPs, whereas that of erythromycin (30 μg) was almost identical to that of 30 μg of ZrO2-Ery NPs.
[0163] In addition, microdilution analysis showed that ZrO2-Amp NPs had greater antimicrobial activity than ZrO2-Ery NPs (Table 3).
[0164] Pathogens ZrO2-Amp NPs (μg / mL) ZrO2-Ery NPs (μg / mL) MIC MBC MIC MBC E coil 0.78 500 0.78 500 B cereus 1.56 500 1.56 500
[0165] BacLight™ fluorescence staining analysis showed almost no red fluorescence in the control group. However, treatment with ZrO2NPs showed less red fluorescence. In contrast, cells treated with ZrO2-Amp NPs and ZrO2-Ery NPs had more red blood cells. ZrO2-Amp NPs and ZrO2-Ery NPs were proven to be promising inhibitors against E. coli and B. cereus. ZrO2-Amp NPs showed higher red blood cell counts compared to ZrO2-Ery NPs (Figs. 8 and 9). Although this invention demonstrated the unexpected antimicrobial activity of ZrO2NPs containing antibiotics, the precise mechanism of their antimicrobial action is still not understood and requires further research. However, it is hypothesized that ZrO2-Amp NPs exhibit antimicrobial activity through oxidative stress, which leads to protein and DNA damage, ribosomal degradation, cell wall and membrane damage, enzyme inactivation, and the release of reactive oxygen species (ROS).
[0167] 4. Conclusion
[0168] This study successfully synthesized and characterized antibiotic-containing ZrO2NPs (ZrO2-Amp-NPs and ZrO2-Ery-NPs) for enhanced antimicrobial activity. Characterization results demonstrated that the ZrO2NPs were irregularly spherical, with an average particle size of 54.67 ± 3.89 d.nm and a PDI of 0.660. The average diameters of ZrO2-Amp NPs and ZrO2-Ery NPs were 73.99 ± 6.79 d.nm and 80.41 ± 4.62 d.nm, respectively, with PDIs of 0.363 and 0.300. The nanoparticles of the present invention exhibited promising antimicrobial activity against E. coli and B. cereus. ZrO2-Amp NPs and ZrO2-Ery NPs were found not to exhibit significant toxicity to normal cells (NIH3T3), chick chorionic villi analysis, and red blood cells, which indicates increased biocompatibility compared to ampicillin and erythromycin.
[0170] Accordingly, the present invention specifies that it has developed antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract and a method for manufacturing the same, as novel nanoparticles formed from Korean thistle leaf extract by loading an antibiotic onto zirconia nanoparticles to enhance biocompatibility, improve wound healing activity, and improve antibacterial activity.
[0172] Although the present invention has been described together with the accompanying drawings, this is merely one example among various embodiments containing the gist of the invention, and its purpose is to enable those skilled in the art to easily implement it; it is clear that the present invention is not limited to the embodiments described above. Accordingly, the scope of protection of the present invention should be interpreted by the claims below, and all technical ideas within an equivalent scope by modification, substitution, replacement, etc., without departing from the gist of the invention shall be included within the rights of the present invention. Furthermore, it is clarified that some components in the drawings are provided in an exaggerated or reduced size compared to the actual form to more clearly explain the configuration. Explanation of the symbols
[0173] (S10): Step for manufacturing Korean thistle leaf extract (S20): Mixed solution preparation step (S30): Zirconia nanoparticle manufacturing step (S40): Preparation step of zirconia nanoparticles capped with antibiotic-loaded Cirsium japonicum leaf extract
Claims
Claim 1 A step for preparing a Korean thistle leaf extract (S10), wherein the Korean thistle leaf powder, obtained by drying and grinding the Korean thistle leaves into powder, is dissolved in purified water and stirred; a step for preparing a mixed solution (S20), wherein the Korean thistle leaf extract from the step for preparing a Korean thistle leaf extract (S10) is added dropwise to a zirconia tetrachloride solution and stirred to prepare a mixed solution; and a step for preparing zirconia nanoparticles (S30), wherein the mixed solution prepared in the step for preparing a mixed solution (S20) is centrifuged to produce zirconia nanoparticles. A method for manufacturing antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles, characterized by including a step (S40) of manufacturing antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles, wherein one or more antibiotics selected from ampicillin or erythromycin are mixed with the zirconia nanoparticles manufactured in the zirconia nanoparticle manufacturing step (S30), centrifuged, and freeze-dried to produce antibiotic-loaded Korean thistle leaf extract-capped zirconia nanoparticles. Claim 2 A method for preparing antibiotic-loaded Korean thistle leaf extract capping zirconia nanoparticles, wherein, in the step (S10) of preparing the Korean thistle leaf extract, the Korean thistle leaf extract is prepared by dissolving the Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, in purified water at a weight ratio of 1:5 and stirring at 80 to 100°C for 20 to 40 minutes. Claim 3 A method for preparing antibiotic-loaded Korean thistle leaf extract capping zirconia nanoparticles, wherein, in claim 1, the mixed solution in the mixed solution preparation step (S20) is prepared by adding the Korean thistle leaf extract from the Korean thistle leaf extract preparation step (S10) dropwise to the zirconia tetrachloride solution and stirring at 100 to 140 rpm for 3 to 4 hours at 40 to 80°C. Claim 4 A method for manufacturing antibiotic-loaded Cirsium japonicum leaf extract-capped zirconia nanoparticles, wherein, in claim 1, the zirconia nanoparticles in the zirconia nanoparticle manufacturing step (S30) are manufactured by centrifuging the mixed solution manufactured in the mixed solution manufacturing step (S20) at 3000 to 5000 rpm for 5 to 15 minutes. Claim 5 A method for preparing antibiotic-loaded zirconia thistle leaf extract capping zirconia nanoparticles according to claim 1, wherein the zirconia nanoparticles loaded with antibiotic in the zirconia nanoparticle manufacturing step (S40) are prepared by mixing one or more antibiotics selected from ampicillin or erythromycin with the zirconia nanoparticles prepared in the zirconia nanoparticle manufacturing step (S30) at a speed of 100 to 140 rpm for 3 to 4 hours, centrifuging, and freeze-drying. Claim 6 A method for preparing antibiotic-loaded zirconia thistle leaf extract capping zirconia nanoparticles according to claim 1, wherein the zirconia nanoparticles loaded with antibiotics in the zirconia nanoparticle manufacturing step (S40) are prepared by mixing one or more antibiotics selected from ampicillin or erythromycin with the zirconia nanoparticles prepared in the zirconia nanoparticle manufacturing step (S30), centrifuging at 3000 to 5000 rpm for 5 to 15 minutes, and freeze-drying for 8 to 16 hours. Claim 7 Antibiotic-loaded zirconia leaf extract capping zirconia nanoparticles characterized by being obtained by centrifuging zirconia nanoparticles prepared by centrifuging one or more antibiotics selected from ampicillin or erythromycin, mixing them with a zirconia tetrachloride solution, and then centrifuging and freeze-drying the mixture of zirconia nanoparticles prepared by adding dropwise a zirconia tetrachloride solution to a zirconia tetrachloride solution and stirring a zirconia tetrachloride leaf extract formed by dissolving zirconia tetrachloride leaf powder (which is obtained by drying and grinding zirconia tetrachloride leaves into purified water and stirring) and centrifuging the mixture, and then centrifuging and freeze-drying the mixture. Claim 8 In claim 7, the above-mentioned Korean thistle leaf extract is characterized by being prepared by dissolving Korean thistle leaf powder, obtained by drying and grinding Korean thistle leaves into powder, in purified water at a weight ratio of 1:5 and stirring at 80 to 100°C for 20 to 40 minutes, thereby producing antibiotic-loaded Korean thistle leaf extract capping zirconia nanoparticles. Claim 9 In claim 7, the antibiotic-loaded Korean thistle leaf extract capping zirconia nanoparticles are characterized by the fact that the mixed solution is prepared by adding the Korean thistle leaf extract dropwise to the zirconia tetrachloride solution and stirring at 100 to 140 rpm for 3 to 4 hours at 40 to 80°C. Claim 10 In claim 7, the zirconia nanoparticles are antibiotic-loaded Korean thistle leaf extract capping zirconia nanoparticles, characterized in that the zirconia nanoparticles are prepared by centrifuging the mixed solution at 3000 to 5000 rpm for 5 to 15 minutes. Claim 11 In claim 7, the antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract are characterized by being prepared by mixing one or more antibiotics selected from ampicillin or erythromycin with the zirconia nanoparticles at a speed of 100 to 140 rpm for 3 to 4 hours, centrifuging, and freeze-drying. Claim 12 In claim 7, the antibiotic-loaded zirconia nanoparticles capped with Korean thistle leaf extract are characterized by being prepared by mixing one or more antibiotics selected from ampicillin or erythromycin with the zirconia nanoparticles, centrifuging at 3000 to 5000 rpm for 5 to 15 minutes, and freeze-drying for 8 to 16 hours.
Citation Information
Patent Citations
Antibiotic composition containing nanostructure
KR1020220021882A
